`Substitute for form 1449/PTO (Revised 07/2005)				Complete if Known			
				Application Number	10/657,550		
TATEOR	N # 4 (E) # (A)	TOTOGEO	CTIDE	Filing Date	09/04/2003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Chaudry 1616		
				Group Art Unit			
(Use as many sheets as necessary)			)	Examiner Name	James Henry Alstrum Acevedo		
Sheet	1	of	1	Attorney Docket Number	048765/277062		

			U.S.	PATENT I	ОС	UMENTS			
Examiner Initials*	Cite No.			Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Relevant Passages of	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
	25	US - 5,976,573	11/0	2/1999		Kim			
		<u>I</u> F(	DREI	GN PATEN	T D	OCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code - Number Kind Code (if known)		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached	
	26	WO 1986/003750		07/03/1986		Riker Laboratories, Inc.		YES	
	27	WO 1999/18971		04/22/1999	9	Harris et al.		YES	
				THER DO	CUN	1ENTS			
Examiner Initials*	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	28	LACY ET AL., 1999-2000 Drug Information Handbook, Lexi-Comp, Inc., 1999, pp. 561-563 and 568-569.							
	29	HEBRECHT et al., "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N.Eng. J. Med., 2002, 347(6), pp. 408-415.							

Examiner	Date
Signature	Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.